Search Results - "Schrock, Alexa B"

Structure-based classification predicts drug response in EGFR-mutant NSCLC by Robichaux, Jacqulyne P., Le, Xiuning, Vijayan, R. S. K., Hicks, J. Kevin, Heeke, Simon, Elamin, Yasir Y., Lin, Heather Y., Udagawa, Hibiki, Skoulidis, Ferdinandos, Tran, Hai, Varghese, Susan, He, Junqin, Zhang, Fahao, Nilsson, Monique B., Hu, Lemei, Poteete, Alissa, Rinsurongkawong, Waree, Zhang, Xiaoshan, Ren, Chenghui, Liu, Xiaoke, Hong, Lingzhi, Zhang, Jianjun, Diao, Lixia, Madison, Russell, Schrock, Alexa B., Saam, Jennifer, Raymond, Victoria, Fang, Bingliang, Wang, Jing, Ha, Min Jin, Cross, Jason B., Gray, Jhanelle E., Heymach, John V.

“…Epidermal growth factor receptor ( EGFR ) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC) 1…”
Get full text

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3 by Ross, Jeffrey S., Fakih, Marwan, Ali, Siraj M., Elvin, Julia A., Schrock, Alexa B., Suh, James, Vergilio, Jo‐Anne, Ramkissoon, Shakti, Severson, Eric, Daniel, Sugganth, Fabrizio, David, Frampton, Garrett, Sun, James, Miller, Vincent A., Stephens, Philip J., Gay, Laurie M.

“…BACKGROUND In contrast to lung cancer, few precision treatments are available for colorectal cancer (CRC). One rapidly emerging treatment target in CRC is…”
Get full text

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer by Lin, Jessica J, Zhu, Viola W, Yoda, Satoshi, Yeap, Beow Y, Schrock, Alexa B, Dagogo-Jack, Ibiayi, Jessop, Nicholas A, Jiang, Ginger Y, Le, Long P, Gowen, Kyle, Stephens, Philip J, Ross, Jeffrey S, Ali, Siraj M, Miller, Vincent A, Johnson, Melissa L, Lovly, Christine M, Hata, Aaron N, Gainor, Justin F, Iafrate, Anthony J, Shaw, Alice T, Ou, Sai-Hong Ignatius

“…Purpose Advanced anaplastic lymphoma kinase ( ALK) fusion-positive non-small-cell lung cancers (NSCLCs) are effectively treated with ALK tyrosine kinase…”
Get full text

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer by Pietrantonio, Filippo, Di Nicolantonio, Federica, Schrock, Alexa B, Lee, Jeeyun, Tejpar, Sabine, Sartore-Bianchi, Andrea, Hechtman, Jaclyn F, Christiansen, Jason, Novara, Luca, Tebbutt, Niall, Fucà, Giovanni, Antoniotti, Carlotta, Kim, Seung Tae, Murphy, Danielle, Berenato, Rosa, Morano, Federica, Sun, James, Min, Bosun, Stephens, Philip J, Chen, Marissa, Lazzari, Luca, Miller, Vincent A, Shoemaker, Robert, Amatu, Alessio, Milione, Massimo, Ross, Jeffrey S, Siena, Salvatore, Bardelli, Alberto, Ali, Siraj M, Falcone, Alfredo, de Braud, Filippo, Cremolini, Chiara

“…ALK, ROS1, and NTRK fusions occur in 0.2% to 2.4% of colorectal cancers. Pioneer cases of metastatic colorectal cancer (mCRC) patients bearing rearrangements…”
Get full text

Clinicopathologic Characteristics of BRG1-Deficient NSCLC by Dagogo-Jack, Ibiayi, Schrock, Alexa B, Kem, Marina, Jessop, Nicholas, Lee, Jessica, Ali, Siraj M, Ross, Jeffrey S, Lennerz, Jochen K, Shaw, Alice T, Mino-Kenudson, Mari

“…Ten percent of NSCLCs harbor mutations in SMARCA4, the gene encoding the SWItch/Sucrose Non-Fermentable ATPase BRG1. In preclinical models, BRG1 inactivation…”
Get more information

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC by Riess, Jonathan W, Gandara, David R, Frampton, Garrett M, Madison, Russell, Peled, Nir, Bufill, Jose A, Dy, Grace K, Ou, Sai-Hong Ignatius, Stephens, Philip J, McPherson, John D, Lara, Jr, Primo N, Burich, Rebekah A, Ross, Jeffrey S, Miller, Vincent A, Ali, Siraj M, Mack, Philip C, Schrock, Alexa B

“…EGFR exon 20 insertions (EGFRex20ins) comprise an uncommon subset of EGFR-activating alterations relatively insensitive to first- and second-generation EGFR…”
Get more information

Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures by Johnson, Adrienne, Severson, Eric, Gay, Laurie, Vergilio, Jo‐Anne, Elvin, Julia, Suh, James, Daniel, Sugganth, Covert, Mandy, Frampton, Garrett M., Hsu, Sigmund, Lesser, Glenn J., Stogner‐Underwood, Kimberly, Mott, Ryan T., Rush, Sarah Z., Stanke, Jennifer J., Dahiya, Sonika, Sun, James, Reddy, Prasanth, Chalmers, Zachary R., Erlich, Rachel, Chudnovsky, Yakov, Fabrizio, David, Schrock, Alexa B., Ali, Siraj, Miller, Vincent, Stephens, Philip J., Ross, Jeffrey, Crawford, John R., Ramkissoon, Shakti H.

“…Background Pediatric brain tumors are the leading cause of death for children with cancer in the U.S. Incorporating next‐generation sequencing data for both…”
Get full text

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation by Brown, Benjamin P, Zhang, Yun-Kai, Westover, David, Yan, Yingjun, Qiao, Huan, Huang, Vincent, Du, Zhenfang, Smith, Jarrod A, Ross, Jeffrey S, Miller, Vincent A, Ali, Siraj, Bazhenova, Lyudmila, Schrock, Alexa B, Meiler, Jens, Lovly, Christine M

“…The third-generation EGFR inhibitor, osimertinib, is the first mutant-selective inhibitor that has received regulatory approval for the treatment of patients…”
Get full text

Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling by Qin, Angel, Johnson, Adrienne, Ross, Jeffrey S, Miller, Vincent A, Ali, Siraj M, Schrock, Alexa B, Gadgeel, Shirish M

“…Activation of the fibroblast growth factor receptor (FGFR) family through fusion with various partners has been described in multiple cancer types, including…”
Get more information

A Pan-Cancer Landscape Analysis Reveals a Subset of Endometrial Stromal and Pediatric Tumors Defined by Internal Tandem Duplications of BCOR by Juckett, Luke T, Lin, Doug I, Madison, Russell, Ross, Jeffrey S, Schrock, Alexa B, Ali, Siraj

“…The Polycomb Repressive Complex 1 (PRC1) regulates epigenetic silencing and is manifestly linked to rare cancer types. The X-linked BCOR gene (BCL-6…”
Get more information

RET rearrangements are actionable alterations in breast cancer by Paratala, Bhavna S., Chung, Jon H., Williams, Casey B., Yilmazel, Bahar, Petrosky, Whitney, Williams, Kirstin, Schrock, Alexa B., Gay, Laurie M., Lee, Ellen, Dolfi, Sonia C., Pham, Kien, Lin, Stephanie, Yao, Ming, Kulkarni, Atul, DiClemente, Frances, Liu, Chen, Rodriguez-Rodriguez, Lorna, Ganesan, Shridar, Ross, Jeffrey S., Ali, Siraj M., Leyland-Jones, Brian, Hirshfield, Kim M.

“…Fusions involving the oncogenic gene RET have been observed in thyroid and lung cancers. Here we report RET gene alterations, including amplification, missense…”
Get full text

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling by Schrock, Alexa B, Li, Shuyu D, Frampton, Garrett M, Suh, James, Braun, Eduardo, Mehra, Ranee, Buck, Steven C, Bufill, Jose A, Peled, Nir, Karim, Nagla Abdel, Hsieh, K Cynthia, Doria, Manuel, Knost, James, Chen, Rong, Ou, Sai-Hong Ignatius, Ross, Jeffrey S, Stephens, Philip J, Fishkin, Paul, Miller, Vincent A, Ali, Siraj M, Halmos, Balazs, Liu, Jane J

“…Pulmonary sarcomatoid carcinoma (PSC) is a high-grade NSCLC characterized by poor prognosis and resistance to chemotherapy. Development of targeted therapeutic…”
Get more information

Genomic Profiling of Small-Bowel Adenocarcinoma by Schrock, Alexa B, Devoe, Craig E, McWilliams, Robert, Sun, James, Aparicio, Thomas, Stephens, Philip J, Ross, Jeffrey S, Wilson, Richard, Miller, Vincent A, Ali, Siraj M, Overman, Michael J

“…Small-bowel adenocarcinomas (SBAs) are rare cancers with a significantly lower incidence, later stage at diagnosis, and worse overall survival than other…”
Get more information

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA by Lee, Jessica K, Hazar-Rethinam, Mehlika, Decker, Brennan, Gjoerup, Ole, Madison, Russell W, Lieber, Daniel S, Chung, Jon H, Schrock, Alexa B, Creeden, James, Venstrom, Jeffrey, Alexander, Brian, Oxnard, Geoffrey R

“…Oncogenic kinase fusions are targetable with approved and investigational therapies and can also mediate acquired resistance (AR) to targeted therapy. We aimed…”
Get full text

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy by Parikh, Aparna R., He, Yuting, Hong, Ted S., Corcoran, Ryan B., Clark, Jeff W., Ryan, David P., Zou, Lee, Ting, David T., Catenacci, Daniel V., Chao, Joseph, Fakih, Marwan, Klempner, Samuel J., Ross, Jeffrey S., Frampton, Garrett M., Miller, Vincent A., Ali, Siraj M., Schrock, Alexa B.

“…Background Alterations in the DNA damage response (DDR) pathway confer sensitivity to certain chemotherapies, radiation, and other DNA damage repair targeted…”
Get full text

Identification of NTRK fusions in pediatric mesenchymal tumors by Pavlick, Dean, Schrock, Alexa B., Malicki, Denise, Stephens, Philip J., Kuo, Dennis J., Ahn, Hyunah, Turpin, Brian, Allen, Justin M., Rosenzweig, Mark, Badizadegan, Kamran, Ross, Jeffrey S., Miller, Vincent A., Wong, Victor, Ali, Siraj M.

“…Background NTRK fusions are known oncogenic drivers and have recently been effectively targeted by investigational agents in adults. We sought to assess the…”
Get full text

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition by Fabrizio, David A, George, Jr, Thomas J, Dunne, Richard F, Frampton, Garrett, Sun, James, Gowen, Kyle, Kennedy, Mark, Greenbowe, Joel, Schrock, Alexa B, Hezel, Aram F, Ross, Jeffrey S, Stephens, Phillip J, Ali, Siraj M, Miller, Vincent A, Fakih, Marwan, Klempner, Samuel J

“…The clinical application of targeting checkpoint inhibitors in colorectal cancer (CRC) has largely focused on a subset of microsatellite instable (MSI-high)…”
Get full text

Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting by Du, Zhenfang, Brown, Benjamin P., Kim, Soyeon, Ferguson, Donna, Pavlick, Dean C., Jayakumaran, Gowtham, Benayed, Ryma, Gallant, Jean-Nicolas, Zhang, Yun-Kai, Yan, Yingjun, Red-Brewer, Monica, Ali, Siraj M., Schrock, Alexa B., Zehir, Ahmet, Ladanyi, Marc, Smith, Adam W., Meiler, Jens, Lovly, Christine M.

“…Mechanistic understanding of oncogenic variants facilitates the development and optimization of treatment strategies. We recently identified in-frame, tandem…”
Get full text

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? by Ou, Sai-Hong Ignatius, Lee, Thomas K, Young, Lauren, Fernandez-Rocha, Maria Y, Pavlick, Dean, Schrock, Alexa B, Zhu, Viola W, Milliken, Jeffrey, Ali, Siraj M, Gitlitz, Barbara J

“…Highlights • SCLC transformation is a resistance mechanism to ALK inhibitors. • Liquid biopsy missed morphologic examination. • Emergence of Rb1 C706Y and p53…”
Get full text

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy by Klempner, Samuel J, Gershenhorn, Bruce, Tran, Phu, Lee, Thomas K, Erlander, Mark G, Gowen, Kyle, Schrock, Alexa B, Morosini, Deborah, Ross, Jeffrey S, Miller, Vincent A, Stephens, Philip J, Ou, Sai-Hong Ignatius, Ali, Siraj M

“…Neuroendocrine tumors comprise a heterogeneous group of malignancies with a broad spectrum of clinical behavior. Poorly differentiated tumors follow an…”
Get more information